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WORKSHOP ON MACROPHAGE ELECTROPHORETIC MOBILITY
(MEM) AND STRUCTUREDNESS OF CYTOPLASMIC
MATRIX (SDM) TESTS
Reported by
K. D. BAGSHAWE
Department of Medical Oncology, Charing Cross Hospital [Fulham], Fulham
Palace Road, London W6 8RF
This was held at Charing Cross Hospital under the auspices ofthe British Association
of Cancer Research, with the support of the Cancer Research Campaign, on 8 and
9 November 1976. The meeting was organized by Dr C. R. Pentycross, Mr G. A.
Rawlins and Professor K. D. Bagshawe of the Department of Medical Oncology,
Charing Cross Hospital.
Practical demonstrations
During the first day, practical demon-
strations were given of the apparatus
and methods used by Pritchard (Cardiff),
Dickinson (Leeds), Forrester (Chester
Beatty), Rawlins (Charing Cross) and
Cercek (Manchester). For the MEM test,
these included the Zeiss cytopherometer
and a new version of the Rank cyto-
pherometer fitted with television and
videotape unit. For the SCM test, the
Perkin-Elmer Polarizing Spectrophoto-
fluorimeter MPF-4 was used by Cercek
and Cercek, and a simplified apparatus
with direct printout of P values was also
demonstrated (Mitchell, Charing Cross),
indicating that less expensive systems
may be suitable.
Macrophage collection was demon-
strated by Dickinson, but different prac-
tices in the participating laboratories,
particularly in the use of liquid paraffin
or Marcol 80 for the production ofguinea-
pig peritoneal macrophages, and the
limited time available, prevented a satis-
factory blind test on the blood specimens
available in the MEM test. Two blood
samples were run blind in the SCM
test: these were correctly identified as
" normal " and " abnormal
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Myelin basic protein, cancer basic protein
A session was then held on myelin
basic protein and cancer basic protein,
under the chairmanship ofProfessor N. A.
Mitchison (U.C.L.). Rumsby (York) out-
lined the structure and chemistry of
MBP, pointing out that it was advan-
tageous to prepare myelin as a first step
in its preparation. Similarities in its
amino-acid sequences with histones were
referred to by Rumsby and Johns (Chester
Beatty). The historical and accidental
events leading to the use of MBP were
described by Caspary (Newcastle). In
reply to Mitchell, Rumsby said he thought
oc-helical structural changes occurred in
MBP on isolation.
Dickinson described his studies on
cancer basic protein (CBP) and suggested
that this was an antigen crossreacting
with MBP but produced by and charac-
teristic of cancer cells. He also described
the use of whole living cells and synthetic
amino-acid sequences which were ap-
parently active in the MEM test. In the
discussion some doubts were expressed
whether the methods employed were
adequate to produce highly homogeneous
peptides, and it was felt that both con-
ventional immunological investigationsK. D. BAGSHAWE
and animal experimentation were re-
quired, to clarify whether these substances
can be regarded as " antigens " in the
tests described.
Bagshawe referred to evidence from
various sources that human chorionic
gonadotrophin (hCG) may be produced
in small amounts by many human tumours
other than trophoblastic elements. Wass
and Rawlins had found positive MEM
responses with hCG in 80%of cancer
patients and 1800 of non-cancer patients.
Positive responses were also obtained
with the a and , subunits of hCG and
desialylated hC(G but not with LH.
Wass outlined the chemistry of the hCG
molecule, which shows no significant
similarities with MBP.
MEM test
On the second day of the workshop,
Dr A. C. Allison (Northwiek Park) took
the chair in a session on the MEM test.
During discussion of techniques, Mehrishi
emphasized the necessity of making mea-
surements only in the stationary layer,
of a 6-sec minimum counting time, and
or presenting raw mobility data. These
conditions were not accepted by Prit-
chard. Forrester said that all labora-
tories should publish their mobility times
for washed human erythrocytes. Dickin-
son and others drew attention to failures
with the test resulting from the use of
macrophages from infected guinea-pigs,
which are
" slow " in the control tubes.
This point was emphasized later when
Mehrishi (Cambridge) reported he could
find no slowing, and Preece pointed out
the slow EM times of his controls.
Forrester agreed that the variation in
EM times had fallen from 10-12o% in
historical data to 3-1 with current
methods of preparation.
Preece (Bristol), Pritchard and Rawlins
found liquid paraffin preferable to Marcol
80 for macrophage production, although
Dickinson found the latter more satis-
factorv. Pritchard said the best macro-
phages were about 16 ,im in diameter,
contained one or more oil droplets, and
should constitute 70-800o of the exudate.
Large and small variants were best
avoided.
In a discussion of statistical analysis,
the view was expressed that the two-
column system of recording EM times,
with rejection of aberrant values, was
undesirable.
Discussion of methods for lymphocyte
collection found agreement that heavily
greased syringes were unsatisfactory and
that there was no ideal anticoagulant:
EDTA was unsatisfactory, excess heparin
could cause interference in the reactions,
and defibrination involved trauma with
uncertain consequences. Some avoided
all plastics, others found them acceptable.
Dyson (Leeds) reported recent ex-
perience using sheep erythrocytes instead
of macrophages. Problems had been en-
countered with fixation methods. Ab-
sorption of the slowing factor to the
erythrocyte was reversible. The possible
use of other inert particles was discussed.
Preece and Pritchard both reported
failure to obtain evidence of sensitization
in the MEM test with PPD, which gave
classical responses in tests for macrophage
migration inhibition. Caspary said the
positive results he had reported had all
been obtained with one batch of PPD
of which very little was left. Antigen
bound to solid support had been used
successfully both by Caspary and Prit-
chard. Mitchison underlined the need
to carry out the classical criss-cross
specificity experiment with myelin and
basic protein, and to raise antibodies to
these substances. Dickinson- said that
multiple sclerosis patients' lymphocytes,
like those of cancer patients, gave better
responses to CBP than to MBP.
Turning to the question whether this
is a cancer test, Pritchard outlined his
results, and emphasized the low incidence
of false negatives in the test. Sutherland
(Cardiff) suggested that finding 13 positive
cases in 105 normal subjects was consistent
with the concept that the test had a
lead-in time of about 15 years before
cancer became clinicallv evident. He
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thought the test might become positive
when there were about 103 cancer cells.
It was generally felt that hard data would
be required before such concepts could
be accepted, and Rawlins showed that for
patients with breast lumps tested before
biopsy the test had given a high rate
(about 20%) of both false positives and
false negatives.
Allison summed up the session by
stating the need for further studies to
clarify the nature of the reagents used,
the characterization of the active lympho-
cytic population, and the lymphokines
involved.
SCM test
The following session on the SCM
test was chaired by Professor Mitchison.
L. Cercek said that various factors which
were not known to be critical when the
test was first described in 1974 had now
been defined, and deviation from these
accounted for the failure of others to
reproduce their observations. The factors
to which she drew special attention were
the isolation of lymphocytes, the control
of pH, Ca ion concentration, osmolarity
of the buffer and fluorescein diacetate
solutions, temperature control and correct
wave-length selection. The selection of
sensitized resting-phase lymphocytes is
dependent on precise control ofthe density
of the Ficoll-Triosil gradient and tem-
perature.
The technique of cell separation had
been demonstrated during the first day
of the Workshop. Attention was also
drawn to the unsatisfactory quality of
the polarizers fitted to many examples
of the Perkin Elmer MPF-4. The effects
of pH, osmolarity, temperature during
measurement and Ca ion concentration
were indicated. The excitation wave-
length at 470 nm with a band width
of 20 nm necessitated a xenon light
source, and B. Cercek said that the
emission wavelength of 510 nm (band
width 10 mm) is also critical and was
determined by the specific fluorophor
being detected only at that wave-length.
He also said that the polarizer should be
located between the cuvette and mono-
chromator.
Steen (Oslo) reported work in which
he had been quite unable to reproduce
the results reported by the Cerceks, but
B. Cercek pointed to discrepancies in the
techniques applied. Stacke Dunne (Glas-
gow) had also been unable to reproduce
their results but he accepted that the
filter combination used and the zinc
light source would be unsuitable if the
theoretical analysis, now put forward by
the Cerceks, and based on a specific
species of fluorophor, was confirmed.
Brocklehurst (ICRF) reported that his
results had shown no significant improve-
ment after two visits to the Cerceks'
laboratory. He asked why the Cerceks
had been able to discriminate between
neoplastic and non-neoplastic states when
the conditions for the test had only now
been defined. L. Cercek said that the
cancer basic protein which he had
used was inactive on testing in their
laboratory, and he measured the emission
at 520 nm, where no changes are expected
to be seen.
Pentycross also reported that many
tests proved uninterpretable and he was
able to achieve discrimination with myelin
basic protein but not at all with phyto-
haemagglutinin. He also referred to low
lymphocyte recovery from cancer patients,
a point confirmed by Stacke Dunne and
others. Pritchard recorded a large num-
ber of results in which there had also
been a failure to discriminate between
cancer and non-cancer states. However,
during the week preceding the Workshop
and following a visit to his laboratory by
the Cerceks, he had changed the condi-
tions for separating lymphocytes to
those nowrecommended, and a smallnum-
ber of samples tested had given results
fully consistent with those of the Cerceks.
Dickinson reported Japanese results
on 36 cases consistent with those reported
by the Cerceks. L. Cercek then sum-
marized the Manchester results. The
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RRSCM value for patients with proven
cancer had averaged 0-76 compared with
1'46 for healthy donors and 1*36 for
those with non-malignant disease. Benign
proliferative diseases gave normal values
and benign breastlumpsgave intermediate
values. Only 2/272 patients with cancer
have given false negative results.
Summing up the immunological as-
pects of the test, Mitchison emphasized
the need to define immunologically active
synthetic peptides and to determine
whether there is an obligatory T-cell
determinant. He drew attention to the
lack of animal experimentation, the
lack of specific antibodies to substances
involved in the reaction, the need to
test for MBP in other systems and the
need to define subsets of T lymphocytes.
New related methods
Kaplan (General Electric Co., U.S.A.)
described a technique using a laser light
source and Doppler principles for measur-
ing the electrophoretic mobility of a
large number of cells in a few seconds.
This provided a distribution curve of
EM times when unstimulated lympho-
cytes were compared with the same
lymphocytes after stimulation by antigen,
when a new peak was defined. Using
preparations of tumour antigen, pre-
liminary results were encouraging.
Bagshawe, winding up, saidthat unless
studies were carried out " blind " there
would always be a suspicion ofunconscious
bias and selection, especially where tech-
niques could not be readily reproduced.
One could not expect 100% reliability
in answer to the question whether a
patient has cancer, and even histopatho-
logical examination could not always
resolve the issue. Reliability approaching
that ofhistopathological examination was
necessary, however, if a test were to have
clinical value.
Editor's note.-Since the workshop
Dr Cercek reports that the SCM test
has been confirmed by Dr Y. Hashimoto,
Faculty of Medicine, University of Tokyo
(100 cases) and by Dr F. Takaku, Jichi
Medical School, Department of Medicine,
Tokyo (27 cases) (Proc. Jap. Cancer
Ass., 35th Annual Meeting, October 1976,
Tokyo); by Dr K. J. Mori, Kyoto Univer-
sity, Department ofMicrobiology, Faculty
of Medicine (private communication) and
by Prof. Dr T. M. Fliedner's group in
Germany, University of Ulm (40 cases,
private communication by Dr S. F
Goldman).
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